Indevus Pharmaceuticals (NASDAQ:[[ticker:IDEV]]) says that a clinical study of its anti-HIV microbicide sponsored by the National Institutes of Health showed the treatment was safe but did not show statistically significant benefits. The 3,100-patient study showed that the drug—a vaginal gel applied before intercourse—lowered the risk of infection by 30 percent, shy of the study’s goal of lowering risk by at least 33 percent. The Lexington, MA-based firm expects to reveal results of a larger, 10,000-patient clinical trial of the microbicide by the end of this year.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
